4.7 Article

A point-based tool to predict conversion from mild cognitive impairment to probable Alzheimer's disease

Journal

ALZHEIMERS & DEMENTIA
Volume 10, Issue 6, Pages 646-655

Publisher

WILEY
DOI: 10.1016/j.jalz.2013.12.014

Keywords

Alzheimer's disease; Mild cognitive impairment; Prognostic modeling; Risk factors; Aged; Human; Magnetic resonance imaging; Neuropsychological tests; Disease progression

Funding

  1. Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health) [U01 AG024904]
  2. National Institute on Aging
  3. National Institute of Biomedical Imaging and Bioengineering
  4. Alzheimer's Association
  5. Alzheimer's Drug Discovery Foundation
  6. BioClinica, Inc.
  7. Biogen Idec, Inc.
  8. Bristol-Myers Squibb Company
  9. Eisai, Inc.
  10. Elan Pharmaceuticals, Inc.
  11. Eli Lilly and Company
  12. F. Hoffmann-La Roche, Ltd.
  13. Genentech, Inc.
  14. GE Healthcare
  15. Innogenetics, N.V.
  16. IXICO, Ltd.
  17. Janssen Alzheimer Immunotherapy Research & Development, LLC
  18. Johnson & Johnson Pharmaceutical Research & Development LLC
  19. Medpace, Inc.
  20. Merck Co., Inc.
  21. Meso Scale Diagnostics, LLC
  22. NeuroRx Research
  23. Novartis Pharmaceuticals Corporation
  24. Pfizer, Inc.
  25. Piramal Imaging
  26. Servier
  27. Synarc, Inc.
  28. Takeda Pharmaceutical Company
  29. Canadian Institutes of Health Research
  30. Northern California Institute for Research and Education
  31. NIH [P30 AGO 10129, K01 AG030514]
  32. S.D. Bechtel, Jr. Foundation
  33. National Institutes of Health
  34. Department of Veterans Affairs
  35. Department of Defense
  36. NARSAD
  37. University of California School of Medicine, S.D.
  38. NIH
  39. Commonwealth Fund
  40. Retirement Research Foundation
  41. American Federation of Aging Research through the Beeson Career Development Award [K23AG040779]
  42. [K24-AG031155]

Ask authors/readers for more resources

Background: Our objective in this study was to develop a point-based tool to predict conversion from amnestic mild cognitive impairment (MCI) to probable Alzheimer's disease (AD). Methods: Subjects were participants in the first part of the Alzheimer's Disease Neuroimaging Initiative. Cox proportional hazards models were used to identify factors associated with development of AD, and a point score was created from predictors in the final model. Results: The final point score could range from 0 to 9 (mean 4.8) and included: the Functional Assessment Questionnaire (2-3 points); magnetic resonance imaging (MRI) middle temporal cortical thinning (1 point); MRI hippocampal subcortical volume (1 point); Alzheimer's Disease Cognitive Scale cognitive subscale (2-3 points); and the Clock Test (1 point). Prognostic accuracy was good (Harrell's c = 0.78; 95% CI 0.75, 0.81); 3-year conversion rates were 6% (0-3 points), 53% (4-6 points), and 91% (7-9 points). Conclusions: A point-based risk score combining functional dependence, cerebral MRI measures, and neuropsychological test scores provided good accuracy for prediction of conversion from amnestic MCI to AD. (C) 2014 The Alzheimer's Association. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available